Evidence map›Paper›PMID 40026657›Full record

ArticleEuropean urology open science2025

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort.

Hilin Yildirim, Anke Richters, Adriaan D Bins, Arnoud W Postema, Maureen J B Aarts, Martijn G H van Oijen, Patricia J Zondervan, Katja K H Aben

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hilin YildirimCancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Anke RichtersDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
Adriaan D BinsDepartment of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Arnoud W PostemaDepartment of Urology, Leiden University Medical Center, Leiden, The Netherlands.
Maureen J B AartsDepartment of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands.
Martijn G H van OijenDepartment of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Patricia J ZondervanDepartment of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Katja K H AbenDepartment of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapy with tyrosine kinase inhibitors (TKIs) was the standard of care for metastatic renal cell carcinoma (mRCC) until recently, when new first-line combinations with immuno-oncology (IO) agents were approved. We evaluated IO uptake in both first-line and later-line treatment in routine clinical practice in the Netherlands. Patients diagnosed with synchronous mRCC between 2018 and 2022 were identified from the population-based Netherlands Cancer Registry ( Patient summary: Since 2019, systemic treatments for metastatic kidney cancer have shifted from drugs targeting selected proteins to immunotherapy. Our results show trends over time for more favorable characteristics among patients receiving systemic treatment and improvements in survival.

Indexed as

Immune checkpoint inhibitorsImmunotherapyMetastatic renal cancerMetastatic renal cell carcinomaOverall survivalSurvival

Identifiers

PMID40026657
PMCPMC11869531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.